I think if the long awaited licensing deal with ICL doesn’t contain an upfront payment like biotechs get when they licence out, or at least a placement to ICL to raise capital, then I think it will be a worry. The last thing the stock needs is another investor presentation, or another trip down under telling us nothing new or even another webcast. Just focus resources on delivering!
I think if the long awaited licensing deal with ICL doesn’t...
-
- There are more pages in this discussion • 66 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
